Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

21 evidence topics · 21 sources

Cetuximab plus platinum and fluorouracil (EXTREME): efficacy results
OutcomeResult
Median overall survival, cetuximab with platinum-based therapy and fluorouracil (n=222), months“10.1”
Median overall survival, platinum-based therapy and fluorouracil (n=220), months“7.4”
Overall survival hazard ratio (95% CI)“0.80 (0.64, 0.98)”
Median progression-free survival, cetuximab arm, months“5.5”
Median progression-free survival, control arm, months“3.3”
Objective response rate, cetuximab arm“35.6%”
Objective response rate, control arm“19.5%”
Amivantamab plus pembrolizumab: OrigAMI-4 cohort 2, first-line, p16-positive oropharyngeal cancer excluded
Enfortumab vedotin plus pembrolizumab: EV-202 first-line cohort

“Eligible patients had R/M HNSCC, programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1, and no prior systemic therapy in the R/M setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary analysis included 41 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sixteen patients achieved a response, and cORR was 39% [95% confidence interval (CI), 24.2–55.5]. The complete response rate was 9.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median PFS was 5.1 months (95% CI, 3.5–not estimable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with p16-positive oropharyngeal cancer ( n = 11), the cORR was 81.8%, in contrast to 23.3% in patients with non-HPV–associated disease ( n = 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“b For oropharyngeal squamous cell carcinoma only, patients without oropharyngeal cancer were considered HPV–negative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients also did not undergo any testing to confirm their HPV status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote